COMMUNIQUÉS West-GlobeNewswire

Le Centre National de Protonthérapie du Portugal sera équipé de deux solutions Proteus®ONE d’IBA
30/06/2026
Louvain-la-Neuve, Belgique, le 30 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026
Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
30/06/2026
The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED [...]
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
30/06/2026
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune [...]
PetVivo Reports Financial and Operational Results for Fiscal 2026
29/06/2026
MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, [...]
Twentyeight Health partners with Clue to expand access to affordable birth control nationwide
29/06/2026
Bridging the gap between daily cycle tracking and provider-led contraceptive care for personalized reproductive health NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Twentyeight Health, the leading women's telehealth [...]
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
30/06/2026
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the [...]
Acorn Health Expands Autism Diagnostic Evaluations in Florida
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Acorn Health, a leading provider of Applied Behavior Analysis (ABA) therapy, has expanded autism diagnostic services in Florida. Comprehensive diagnostic evaluations [...]
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
29/06/2026
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical [...]
Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio
29/06/2026
HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra [...]
JellyFil Documents 2026 Supplement Facts Panel Composition, 8-Ingredient Proprietary Blend, and Manufacturing Disclosure for Its Gummy Dietary Supplement
29/06/2026
Once-daily men's gummy supplement featuring Maca, Ashwagandha, Tribulus, Arginine, Muira Puama, and Catuaba with 60-day money-back guarantee Largo, FL, June 29, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossier
29/06/2026
Châtillon, France, le 29 juin (22 :00 CEST) 2026 DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans ; la Société travaille en collaboration avec [...]
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
29/06/2026
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in [...]
Lakefront Receives Transparency Notification from Madison Avenue Partners
29/06/2026
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian [...]
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
29/06/2026
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement- [...]
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
29/06/2026
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and [...]
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
29/06/2026
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité L’obéfazimod a apporté [...]
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
29/06/2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database [...]
Dragon Pharma Store Announces Expansion of Research Product Catalog with Addition of KLOW 80mg
29/06/2026
New York, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Dragon Pharma Store announced the addition of KLOW 80mg to its online research product catalog, reflecting continued expansion of available laboratory research materials [...]

Pages